Citadel Securities LLC recently announced the acquisition of new stake in Jaguar Health Inc. (NASDAQ:JAGX). This fresh investment now brings its stake to 0.66% valued currently at $25657.0. In addition, Renaissance Technologies LLC raised its holdings by 2782.0 to 12516.0 shares. And Morgan Stanley & Co. LLC has lifted its position by 123.63% or 1805.0 shares – to 3265.0 shares.
With over 7.15 million Jaguar Health Inc. (JAGX) shares trading Tuesday and a closing price of $1.05 on the day, the dollar volume was approximately $7.51 million. The shares have shown a negative half year performance of -93.67% and its price on 03/14/23 lost nearly -3.67%. Currently, there are 1.94M common shares owned by the public and among those 1.62M shares have been available to trade.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for JAGX have a consensus price objective of $150.00. The analysts have set the share’s price value over the next 12 months at a high of $150.00 and a low of $150.00. The average price target is 99.65% above its recent price level and an upside to the estimated low will see the stock gain 99.3% over that period. But an upside of 99.3% will see the stock hit the forecast high price target while median target price for the stock is $150.00.
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 10 of these insider trades were purchases, accounting for 122,694 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Jaguar Health Inc. are Vanguard Extended Market Index Fu, iShares Core S&P Total US Stock M, and Vanguard Total Stock Market Index. Vanguard Extended Market Index Fu owns 14381.0 shares of the company’s stock, all valued at over $27612.0. The company sold 1.0 shares recently to bring their total holdings to about 0.71% of the shares outstanding. iShares Core S&P Total US Stock M bought 19.0 shares to see its total holdings expand to 11274.0 shares valued at over $21646.0 and representing 0.56% of the shares outstanding. Vanguard Total Stock Market Index sold 2.0 shares to bring its total holdings to over 5977.0 shares at a value of $11476.0. Vanguard Total Stock Market Index now owns shares totaling to 0.30% of the shares outstanding.
Shares of Jaguar Health Inc. (NASDAQ: JAGX) opened at $1.10, up $0.01 from a prior closing price of $1.09. However, the script later moved the day high at 1.3900, down -3.67%. The company’s stock has a 5-day price change of -26.06% and -87.27% over the past three months. JAGX shares are trading -83.89% year to date (YTD), with the 12-month market performance down to -96.41% lower. It has a 12-month low price of $1.05 and touched a high of $61.12 over the same period. JAGX has an average intraday trading volume of 559.10K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -51.24%, -75.69%, and -92.09% respectively.
Institutional ownership of Jaguar Health Inc. (NASDAQ: JAGX) shares accounts for 3.90% of the company’s 1.94M shares outstanding. Mutual fund holders own 1.84%, while other institutional holders and individual stakeholders account for 2.00% and — respectively.
It has a market capitalization of $2.27M and a beta (3y monthly) value of 1.95. The earnings-per-share (ttm) stands at -$58.95. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.15% over the week and 12.07% over the month.
Analysts forecast that Jaguar Health Inc. (JAGX) will achieve an EPS of -$9.75 for the current quarter, $0 for the next quarter and -$37.5 for 2023. The lowest estimate earnings-per-share for the quarter is -$9.75 while analysts give the company a high EPS estimate of -$9.75. Comparatively, EPS for the current quarter was -$23.25 a year ago. Earnings per share for the fiscal year are expected to increase by 60.80%, and 35.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Jaguar Health Inc. (JAGX) as a “Strong Buy” at a consensus score of 1.50. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the JAGX, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on July 07, 2021, with the firm’s price target at $5. Rodman & Renshaw coverage for the Jaguar Health Inc. (JAGX) stock in a research note released on July 11, 2017 offered a Buy rating with a price target of $2.
